<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Capecitabine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Capecitabine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Capecitabine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11667" href="/d/html/11667.html" rel="external">see "Capecitabine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708655"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Vitamin K antagonist interaction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking capecitabine concomitantly with oral vitamin K antagonists, such as warfarin. Clinically significant increases in prothrombin time (PT) and international normalized ratio (INR) have been reported in patients who were on stable doses of a vitamin K antagonist at the time capecitabine was introduced. These events occurred within several days and up to several months after initiating capecitabine and, in a few cases, within 1 month after stopping capecitabine. These events occurred in patients with and without liver metastases. Monitor INR more frequently and adjust the dose of the vitamin K antagonist as appropriate.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F145140"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xeloda</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866183"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Capecitabine;</li>
<li>Mint-Capecitabine;</li>
<li>SANDOZ Capecitabine;</li>
<li>TARO-Capecitabine;</li>
<li>TEVA-Capecitabine [DSC];</li>
<li>Xeloda [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F145191"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimetabolite;</li>
<li>
                        Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)</li></ul></div>
<div class="block doa drugH1Div" id="F145144"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b> Baseline platelets should be ≥100,000/mm<sup>3</sup> and neutrophils should be ≥1,500/mm<sup>3</sup> prior to capecitabine initiation. Optimize hydration prior to capecitabine initiation. The capecitabine dose should be rounded to the nearest 150 mg to provide the dose as whole tablets.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1dbb6447-35bc-49b2-826f-4e8b8b0cdaa6">Anal carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anal carcinoma (off-label use): Oral:</b> 825 mg/m<sup>2</sup> twice daily 5 days/week (Monday through Friday) (in combination with mitomycin [on day 1 only]) during radiation therapy; radiation therapy occurred over 5 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26691173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26691173'])">Ref</a></span>) <b>or</b> 825 mg/m<sup>2</sup> twice daily on radiation therapy days (in combination with mitomycin [on day 1 only] and radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25167226','lexi-content-ref-24885554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25167226','lexi-content-ref-24885554'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9fdc525d-5f7d-4513-9933-4cf238a80bef">Biliary tract cancer, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, adjuvant therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monotherapy (adjuvant): </i>
<b>Oral: </b>1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30922733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30922733'])">Ref</a></span>). Per the American Society of Clinical Oncology guideline for adjuvant therapy for resected biliary tract cancer, the capecitabine dose may be determined by institutional and regional practices (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30856044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30856044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chemoradiotherapy (adjuvant):</i>
<b>Oral:</b> 750 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle (in combination with gemcitabine) for 4 cycles, followed by capecitabine 665 mg/m<sup>2</sup> twice daily (in combination with concurrent radiotherapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25964250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25964250'])">Ref</a></span>). Refer to protocol for specific details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="30389bd9-ee54-4903-872d-21fd0d3988cd">Biliary tract cancers, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancers, advanced (off-label use):</b>
<b>Oral:</b> 650 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with gemcitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15800324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15800324'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18182984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18182984'])">Ref</a></span>) <b>or</b> 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with cisplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12853355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12853355'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2c111fe-d487-4147-94fc-f35cb8542a9a">Breast cancer, adjuvant therapy, triple-negative, with residual disease after neoadjuvant therapy and surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, adjuvant therapy, triple-negative, with residual disease after neoadjuvant therapy and surgery (off-label use)</b>: <b>Oral:</b> 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28564564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28564564'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b32fca0-7c36-4eb5-bbdb-f083eb09a582">Breast cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Single-agent therapy: <b>Oral:</b> 1,000 or 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 every 21 days until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15710946','lexi-content-ref-14962720','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15710946','lexi-content-ref-14962720','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Capecitabine/docetaxel: <b>Oral:</b> 1,000 or 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 every 21 days (in combination with docetaxel) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12065558','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12065558','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Breast cancer, metastatic (off-label dosing): Adults ≥65 years of age: <b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle for at least 2 and up to 6 cycles or longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15710946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15710946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Breast cancer, metastatic (off-label combination): <b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with ixabepilone) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Breast cancer, metastatic, HER2+ (off-label combinations): <b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with lapatinib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17192538']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17192538'])">Ref</a></span>) <b>or</b> 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with trastuzumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17679724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17679724'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with tucatinib and trastuzumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31825569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31825569'])">Ref</a></span>) <b>or </b>750 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with neratinib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32678716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32678716'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with margetuximab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33480963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33480963'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Breast cancer, metastatic, HER2+ with brain metastases, first-line therapy (off-label combination): <b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with lapatinib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23122784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23122784'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b39dab5-f5ca-4dde-9071-ab66ae1272b6">Colorectal cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Colon cancer, stage 3, adjuvant therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Single-agent therapy: <b>Oral:</b> 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle for a maximum of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15987918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15987918'])">Ref</a></span>). <b>Note</b>
<b>: </b>Capecitabine toxicities, particularly hand-foot syndrome, may be higher in North American populations; in some patients, therapy initiation at doses of 1,000 mg/m<sup>2</sup> twice daily (on days 1 to 14 every 21 days) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18445840']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18445840'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">XELOX/CAPOX regimen: <b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle (in combination with oxaliplatin) for a maximum of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21383294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21383294'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Colorectal cancer, unresectable or metastatic:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Single-agent therapy: <b>Oral:</b> 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle; continue until disease progression or unacceptable toxicity. <b>Note: </b>Capecitabine toxicities, particularly hand-foot syndrome, may be higher in North American populations; therapy initiation at doses of 1,000 mg/m<sup>2</sup> twice daily (on days 1 to 14 every 21 days) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18445840']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18445840'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">XELOX/CAPOX regimen: <b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle (in combination with oxaliplatin); continue until disease progression or unacceptable toxicity. Some studies administered for a duration of 8 or 16 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18421053','lexi-content-ref-21383294','lexi-content-ref-17194911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18421053','lexi-content-ref-21383294','lexi-content-ref-17194911'])">Ref</a></span>). A retrospective evaluation of a modified schedule (eg, days 1 to 7 and days 15 to 21 of a 28-day cycle) found improved tolerability and no difference in efficacy outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33741260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33741260'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CAPOX/panitumumab: <b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 every 3 weeks (in combination with oxaliplatin and panitumumab) for at least 6 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29855806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29855806'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rectal cancer, locally advanced, perioperative treatment:</i>
<b>Note:</b> Refer to protocol for additional/full details.</p>
<p style="text-indent:-2em;margin-left:6em;">When administered <b>with </b>concomitant radiation therapy: <b>Oral:</b> 825 mg/m<sup>2</sup> twice daily throughout radiotherapy (as part of a perioperative combination regimen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22503032','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22503032','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">When administered <b>without</b> concomitant radiation therapy: <b>Oral:</b> 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle (as part of a perioperative combination regimen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22503032','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22503032','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da226082-fb37-4986-9df7-c938402c83f8">Esophageal, gastric, and gastroesophageal cancers</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal, gastric, and gastroesophageal cancers:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Esophageal, gastric, or gastroesophageal junction cancer, locally advanced (unresectable) or metastatic: <b>Oral:</b> 625 mg/m<sup>2</sup> twice daily on days 1 to 21 every 3 weeks (in combination with platinum-based chemotherapy) for a maximum of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18172173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18172173'])">Ref</a></span>) or 850 or 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 every 3 weeks (in combination with oxaliplatin) until disease progression or unacceptable toxicity; individualize capecitabine dose based on risk factors and tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16303863','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16303863','lexi-content-ref-Manu.1'])">Ref</a></span>) <b>or </b>(off-label combination) 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with oxaliplatin and nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34102137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34102137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Esophageal or gastroesophageal cancers: Preoperative or definitive chemoradiation: <b>Oral:</b> 800 mg/m<sup>2</sup> twice daily on days 1 to 5 weekly (in combination with cisplatin and radiation) for 5 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17951334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17951334'])">Ref</a></span>) <b>or</b> 625 mg/m<sup>2</sup> twice daily on days 1 to 5 weekly (in combination with oxaliplatin and radiation) for 5 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19235592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19235592'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gastric cancer: Postoperative chemoradiation: <b>Oral:</b> 625 to 825 mg/m<sup>2</sup> twice daily during radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16489675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16489675'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gastric or gastroesophageal junction cancer, metastatic, HER2 overexpressing: <b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 every 21 days for 6 cycles (in combination with cisplatin and trastuzumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20728210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20728210'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 every 21 days (in combination with oxaliplatin, pembrolizumab, and trastuzumab) until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34912120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34912120'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gastric or gastroesophageal junction cancer: Locally advanced or metastatic (chemoradiation not indicated): <b>Oral:</b> 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (as a single agent) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15319239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15319239'])">Ref</a></span>) <b>or</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with cisplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19153121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19153121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Gastroesophageal cancer, advanced, palliative treatment: Frail and/or elderly patients: <b>Oral:</b> A dose optimization study that examined 60%, 80%, or 100% of a 625 mg/m<sup>2</sup> twice daily dose (on days 1 to 21 of a 21-day cycle; in combination with oxaliplatin) found that the 60% dose was not inferior (for progression-free survival) and had less toxicity compared to the full dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33983395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33983395'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8622df9c-6f22-4ef3-925b-69648a7a4562">Gastric cancer, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer, adjuvant therapy (off-label use): Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 every 3 weeks for 8 cycles (in combination with oxaliplatin) following D2 gastrectomy in patients who did not receive preoperative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22226517','lexi-content-ref-25439693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22226517','lexi-content-ref-25439693'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="713d1678-ae4b-4795-b6af-b7c9a29c2d0f">Head and neck cancer: Nasopharyngeal carcinoma, locally advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer: Nasopharyngeal carcinoma, locally advanced (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction therapy: </i>
<b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with concurrent radiation therapy and cisplatin); refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32497261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32497261'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant therapy:</i>
<b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle for 8 cycles beginning 4 weeks after concurrent chemoradiotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36227615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36227615'])">Ref</a></span>) <b>or</b> (metronomic dosing) 650 mg/m<sup>2</sup> twice daily for 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34111416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34111416'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b5a99eb9-16c1-4ec6-a39b-777e28bafd24">Head and neck cancer, squamous cell, recurrent or metastatic; palliative treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer, squamous cell, recurrent or metastatic; palliative treatment (off-label use; based on limited data): Oral:</b> 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 21-day treatment cycle for at least 3 cycles; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20485287']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20485287'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79fad62-a2e8-47a1-8d65-a54bda65c2f8">Neuroendocrine tumors: GI/carcinoid, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumors: GI/carcinoid, refractory (off-label use): Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 2 to 15 of a 3-week cycle (in combination with oxaliplatin) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16937105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16937105'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4147399b-d799-4359-9ad2-624654191b56">Neuroendocrine tumors: Pancreatic/islet cell, metastatic or unresectable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumors: Pancreatic/islet cell, metastatic or unresectable (off-label use) Based on limited data:</b>
<b>Oral:</b> 750 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 4-week cycle (in combination with temozolomide) until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20824724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20824724'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a460a566-b92c-419f-a442-c2d18370c92c">Ovarian, fallopian tube, or peritoneal cancer, platinum-refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian, fallopian tube, or peritoneal cancer, platinum-refractory (off-label use):</b>
<b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16516276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16516276'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ccef4479-b48f-40bb-a0b8-4d5b64d7eb76">Pancreatic cancer, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, locally advanced or metastatic (off-label use): Oral:</b> 1,250 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (as a single agent) until disease progression or up to 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11773165']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11773165'])">Ref</a></span>) <b>or</b> 830 mg/m<sup>2</sup> twice daily on days 1 to 21 of a 4-week cycle (in combination with gemcitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19858379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19858379'])">Ref</a></span>) <b> or</b> 1,000 mg/m<sup>2</sup> twice daily (750 mg/m<sup>2</sup> twice daily for patients &gt;65 years of age) on days 1 to 14 of a 3-week cycle (in combination with oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18756532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18756532'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a39e464-8bb6-4795-a1b3-a3b1646f0ac0">Pancreatic cancer, potentially curable, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, potentially curable, adjuvant therapy (alternative therapy):</b>
<b>Note:</b> American Society of Clinical Oncology guidelines for potentially curable pancreatic cancer recommend 6 months of adjuvant therapy if recovery is complete; while first-line therapy with another regimen is preferred, the capecitabine/gemcitabine regimen is an option if toxicity/tolerance are concerns with the preferred therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 830 mg/m<sup>2 </sup>twice daily on days 1 to 21 every 28 days beginning within 12 weeks of resection (in combination with gemcitabine) until disease progression or unacceptable toxicity or for a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28129987','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28129987','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80e1258c-674d-41d4-a1b2-d3be69bcf8cf">Small bowel adenocarcinoma, advanced unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small bowel adenocarcinoma, advanced unresectable or metastatic</b>
<b> (off-label use): </b>
<i>CAPOX regimen: </i>
<b>Oral: </b>750 mg/m<sup>2</sup> twice daily on days 1 to 14 every 3 weeks (in combination with oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19164203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19164203'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c21d4f7-c73b-416e-8ef1-a9549a182e99">Thymic malignancies, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thymic malignancies, refractory (off-label use):</b>
<i> CAP-GEM regimen:</i>
<b> Oral: </b>650 mg/m<sup>2</sup> twice daily on days 1 to 14 every 21 days (in combination with gemcitabine) until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19880439','lexi-content-ref-25471029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19880439','lexi-content-ref-25471029'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="43643979-57e2-4862-91c6-87fa4ec92fb9">Unknown primary cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unknown primary cancer (off-label use):</b>
<b>Oral:</b> 1,000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with oxaliplatin) for up to 6 cycles or until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20209610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20209610'])">Ref</a></span>) <b>or</b> 800 mg/m<sup>2</sup> twice daily on days 1 to 14 of a 3-week cycle (in combination with carboplatin and gemcitabine) for up to 8 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17594717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17594717'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Missed doses:</i> Do not replace missed doses, instead resume with the next planned capecitabine dose. If a dose is vomited, continue with the next scheduled dose; do not administer an additional dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991356"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney impairment prior to treatment initiation:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Capecitabine and its metabolites are primarily (&gt;95%) excreted by the kidneys (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). An increased incidence of drug-limiting toxicity has been observed with declining kidney function, including in patients with eGFR 60 to 90 mL/minute/1.73 m<sup>2</sup> as compared to eGFR &gt;90 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33452614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33452614'])">Ref</a></span>), although another study did not find a difference in toxicity based on CrCl using dose-adjusted capecitabine in patients with breast cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26755510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26755510'])">Ref</a></span>). As such, monitoring for adverse effects (eg, diarrhea, hematologic, mucositis, hand-foot syndrome/palmar-plantar erythrodysesthesia) is warranted even in mild kidney impairment, and toxicity-related dose reductions may be required. Kidney function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute: Administer 75% of the usual indication-specific daily dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181','lexi-content-ref-11935215','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181','lexi-content-ref-11935215','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: A dose has not been established (manufacturer's labeling), and use is generally not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181','lexi-content-ref-11935215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181','lexi-content-ref-11935215'])">Ref</a></span>). If no treatment alternative exists, capecitabine treatment can be considered on an individual basis utilizing a reduced starting dose with close monitoring and dose modification guided by adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). There are limited case reports demonstrating tolerability in this population following dose reductions of up to 80% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22392964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22392964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post-trauma or post-major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Use is generally not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>). If no treatment alternative exists, capecitabine treatment can be considered on an individual basis utilizing a reduced starting dose with close monitoring and dose modification guided by adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Tolerability following dose reduction has been observed in several case reports in hemodialysis patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22392964','lexi-content-ref-31243213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22392964','lexi-content-ref-31243213'])">Ref</a></span>); however, due to the paucity of data, no specific dosage recommendation can be suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Use not recommended (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT: </b>Use not recommended (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Use not recommended (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney toxicity during treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">Capecitabine does not directly damage the kidney (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nemecek.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nemecek.1'])">Ref</a></span>). However, its ability to cause diarrhea and dehydration can impact kidney function. Monitor, intensify supportive care, and correct dehydration. Withhold capecitabine and then resume at the same or at a reduced dose or permanently discontinue based on severity and occurrence. Refer to "Dosing: Adjustment for Toxicity" for dosage adjustment levels.</p></div>
<div class="block doha drugH1Div" id="F50988413"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No initial dose adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16131047','lexi-content-ref-30942181','lexi-content-ref-17914077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16131047','lexi-content-ref-30942181','lexi-content-ref-17914077'])">Ref</a></span>); however, carefully monitor patients with hepatic dysfunction due to liver metastases.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b> Hyperbilirubinemia: Withhold capecitabine and then resume at the same or at a reduced dose or permanently discontinue based on severity and occurrence. For grade 3 or 4 hyperbilirubinemia, interrupt treatment until resolved to ≤ grade 2 (bilirubin ≤3 times ULN). Refer to “Dosing: Adjustment for Toxicity” for dosage adjustment levels.</p></div>
<div class="block doo drugH1Div" id="F20339785"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>American Society of Clinical Oncology guidelines for appropriate chemotherapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>: </b>Utilize patient's actual body weight for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F145192"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor carefully for toxicity and adjust dose as necessary. Doses reduced for toxicity should not be increased at a later time. For combination therapy, also refer to docetaxel product labeling for docetaxel dose modifications. If treatment delay is required for either capecitabine or docetaxel, withhold both agents until appropriate to resume combination treatment. Other concomitant anticancer therapies may also require dosage modification.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Recommended Capecitabine<sup>a</sup> Dose Modifications</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Toxicity Grades</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>During a Course of Therapy</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Dose Adjustment for Next Cycle (% of starting dose)</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> When capecitabine is administered in combination with docetaxel, withhold both capecitabine and docetaxel until the requirements for resuming both medications are met.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Also refer to dose modification recommendations based on toxicity grade listed above.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">Grade 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1st appearance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt until resolved to grade 0 to 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">100%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2nd appearance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt until resolved to grade 0 to 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">75%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3rd appearance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt until resolved to grade 0 to 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">50%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4th appearance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue treatment permanently</p></td>
<td align="center"></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1st appearance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt until resolved to grade 0 to 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">75%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2nd appearance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt until resolved to grade 0 to 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">50%</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3rd appearance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue treatment permanently</p></td>
<td align="center"></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">1st appearance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue permanently</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">
<b>or</b></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">If in the patient's best interest to continue, interrupt until resolved to grade 0 to 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">50%</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Management o</b>
<b>f specific capecitabine toxicities<sup>b</sup></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adverse reaction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Severity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Capecitabine dosage modification</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiotoxicity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">n/a</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold capecitabine as appropriate; the safety of resuming capecitabine following cardiotoxicity has not been established.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dehydration</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥ grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Optimize hydration before restarting. Withhold capecitabine and then resume at the same or at a reduced dose or permanently discontinue based on severity and occurrence.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dermatologic toxicity: Cutaneous adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue capecitabine.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">GI toxicity: Diarrhea</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥ grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold capecitabine and then resume at the same or at a reduced dose or permanently discontinue based on severity and occurrence. Antidiarrheal therapy (eg, loperamide) is recommended to manage diarrhea.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold capecitabine and then resume at the same or at a reduced dose or permanently discontinue based on the occurrence.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥ grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold capecitabine and then resume at the same or at a reduced dose or permanently discontinue based on severity and occurrence.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Evidence of acute early-onset or unusually severe toxicity indicative of dihydropyrimidine dehydrogenase deficiency</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold or permanently discontinue capecitabine depending on the onset, duration, and severity of toxicity.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Capecitabine dosage adjustments for hematologic toxicity when used in combination therapy with ixabepilone:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Neutrophils &lt;500/mm<sup>3</sup> for ≥7 days or neutropenic fever: Hold capecitabine for concurrent diarrhea or stomatitis until neutrophils recover to &gt;1,000/mm<sup>3</sup>, then continue at same dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Platelets &lt;25,000/mm<sup>3</sup> (or &lt;50,000/mm<sup>3</sup> with bleeding): Hold capecitabine for concurrent diarrhea or stomatitis until platelets recover to &gt;50,000/mm<sup>3</sup>, then continue at same dose.</p></div>
<div class="block doe drugH1Div" id="F145145"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F57215963"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone marrow depression</b> may occur, including <b>anemia</b>, <b>neutropenia,</b> and <b>thrombocytopenia</b>. Genetic variants in the DPYD gene (ie, poor metabolizers) increase risk for acute early-onset or severe toxicity due to total or near total absence of dihydropyrimidine dehydrogenase (DPD) enzyme activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31382864']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31382864'])">Ref</a></span>). Patients with partial DPD activity are also at risk. No capecitabine dose has been shown safe in patients with total DPD deficiency; data are insufficient to recommend a dose in patients with partial DPD activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29152729','lexi-content-ref-23988873','lexi-content-ref-28520372','lexi-content-ref-31745289']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29152729','lexi-content-ref-23988873','lexi-content-ref-28520372','lexi-content-ref-31745289'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to mechanism of action; directly toxic to rapidly replicating cells, including bone marrow (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15763604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15763604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic variants in the DPYD gene, resulting in total or partial absence of DPD enzyme activity</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent cytotoxic medications</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiotoxicity has been observed with fluoropyrimidine therapy, including capecitabine. Adverse events include <b>acute myocardial infarction</b>, <b>angina pectoris</b>,<b> ischemic heart disease</b>, <b>cardiac arrhythmia</b>, <b>cardiomyopathy</b>, and <b>heart failure</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31931649','lexi-content-ref-15763604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31931649','lexi-content-ref-15763604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; coronary vasospasm is a potential mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31931649','lexi-content-ref-8391384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31931649','lexi-content-ref-8391384'])">Ref</a></span>). Other proposed mechanisms include endothelial damage, oxidative stress, Krebs cycle disturbances and toxic metabolites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34640443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34640443'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; fluoropyrimidine cardiotoxicity typically occurs several hours after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31931649','lexi-content-ref-32162823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31931649','lexi-content-ref-32162823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting cardiac disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31931649','lexi-content-ref-34640443','lexi-content-ref-32162823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31931649','lexi-content-ref-34640443','lexi-content-ref-32162823'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypercholesterolemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31931649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31931649'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tobacco smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31931649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31931649'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent bevacizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31931649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31931649'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior or concurrent radiation therapy to the chest (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34640443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34640443'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High levels of exertion during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35641220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35641220'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions (including hand-and-foot syndrome)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Capecitabine may cause hand-and-foot syndrome (HFS) (<b>palmar-plantar erythrodysesthesia</b> or chemotherapy-induced acral erythema), characterized by numbness, dysesthesia/paresthesia, tingling, painless or painful swelling, erythema, desquamation, blistering, and severe pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21174613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21174613'])">Ref</a></span>). Post-inflammatory hyperpigmentation is common (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27718746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27718746'])">Ref</a></span>). Persistent HFS (grade ≥2) could eventually lead to fingerprint loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34609922','lexi-content-ref-31558182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34609922','lexi-content-ref-31558182'])">Ref</a></span>). <b>Stevens-Johnson syndrome</b> (SJS) and <b>toxic epidermal necrolysis </b>(TEN) have been reported (some fatal) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28066869','lexi-content-ref-34162250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28066869','lexi-content-ref-34162250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: HFS: Dose-related; may be caused by cyclooxygenase inflammatory-type reaction, accumulation of capecitabine metabolites, and effects of enzymes and transporters in the skin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27631426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27631426'])">Ref</a></span>). SJS/TEN: Non–dose-related, immunologic. Delayed hypersensitivity reactions, including SJS and TEN, are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; HFS median time to onset was ~2.6 months (range: 11 days to ~1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17022868']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17022868'])">Ref</a></span>). Severe cutaneous adverse reactions, such as SJS/TEN usually occur 1 to 8 weeks after initiation, with cases associated with capecitabine occurring 10 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-28066869','lexi-content-ref-34162250','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-28066869','lexi-content-ref-34162250','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (HFS):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27718746','lexi-content-ref-31469628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27718746','lexi-content-ref-31469628'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Early onset (ie, within 21 days) of grade 1 HFS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26160973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26160973'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent bevacizumab or docetaxel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15342618','lexi-content-ref-26160973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15342618','lexi-content-ref-26160973'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of fluorinated pyrimidine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26160973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26160973'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Elevation of serum or red blood cell folate levels, or folate supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28715540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28715540'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic variants, including DPYD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21174613','lexi-content-ref-28715540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21174613','lexi-content-ref-28715540'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26160973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26160973'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Capecitabine may cause GI toxicity, leading to <b>diarrhea</b> and <b>stomatitis</b>, which may be severe. Genetic variants in the DPYD gene (ie, poor metabolizers) increase risk for acute early-onset or severe toxicity due to total or near total absence of dihydropyrimidine dehydrogenase (DPD) enzyme activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31745289']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31745289'])">Ref</a></span>). Dehydration may occur rapidly in patients with diarrhea, <b>nausea</b>, <b>vomiting</b>, and <b>anorexia</b>. <b>Necrotizing enterocolitis</b> (typhlitis) has also been reported. <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to mechanism of action. Directly toxic to fast replicating cells, including those of the GI tract. Thymidine phosphorylase, the enzyme responsible for conversion to active drug, is expressed at higher levels in the GI tract (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15763604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15763604'])">Ref</a></span>). Destruction of the epithelium leads to mucositis throughout the GI tract, leading to diarrhea, stomatitis, nausea/vomiting and typhlitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15763604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15763604'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to first occurrence of grade 2 to 4 diarrhea is 34 days (range: 1 day to 1 year) with a duration of 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31469628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31469628'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic variants in DPYD, resulting in partial or total absence of DPD enzyme activity</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34348673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34348673'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34348673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34348673'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34348673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34348673'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F145108"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (27% to 37%), palmar-plantar erythrodysesthesia (54% to 60%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (14% to 35%), anorexia (≤23%), constipation (≤15%), decreased appetite (26%), diarrhea (47% to 57%; grades 3/4: 2% to 13%), nausea (34% to 53%; grades 3/4: 2% to 4%), stomatitis (22% to 25%; grades 3/4: ≤7%), vomiting (15% to 37%; grades 3/4: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (72% to 80%, grades 3/4: ≤3%)<span class="lexi-table-link-container"> (<a aria-label="Anemia table link" class="lexi-table-link" data-table-id="lexi-content-anemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anemia')">table 1</a>)</span><span class="table-link" style="display:none;">Anemia</span>, lymphocytopenia (94%; grades 3/4: 15% to 44%), neutropenia (13% to 26%; grades 3/4: 1% to 3%)<span class="lexi-table-link-container"> (<a aria-label="Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia')">table 2</a>)</span><span class="table-link" style="display:none;">Neutropenia</span>, thrombocytopenia (24%; grades 3/4: 1% to 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anemia" frame="border" id="lexi-content-anemia" rules="all">
<caption style="text-align:center;">
<b>Capecitabine: Adverse Reaction: Anemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Capecitabine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (5-FU and Leucovorin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Capecitabine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (5-FU and Leucovorin)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 72%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3: 3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 80%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">79%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic colorectal cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">596</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">593</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3: 2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic colorectal cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">596</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">593</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: &lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic colorectal cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">596</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">593</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia" frame="border" id="lexi-content-neutropenia" rules="all">
<caption style="text-align:center;">
<b>Capecitabine: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Capecitabine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (5-FU and Leucovorin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Capecitabine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (5-FU and Leucovorin)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3: 2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">46%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic colorectal cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">596</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">593</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic colorectal cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">596</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">593</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4: 2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,250 mg/m<sup>2</sup> twice a day for 2 weeks followed by a 1-week rest period</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic colorectal cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">596</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">593</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (22% to 48%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≤42%), fatigue (≤42%), pain (≤12%), paresthesia (21%; grade 3: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye irritation (13% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, bradycardia, chest pain, hypertension, hypotension, myocarditis, pulmonary embolism, tachycardia, venous thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, dermal ulcer, diaphoresis, erythema of skin, nail disease, pruritus, skin discoloration, skin photosensitivity, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Cachexia, decreased serum calcium (grades 3/4: 2%), dehydration, hot flash, hypertriglyceridemia, hypokalemia, hypomagnesemia, increased serum calcium (grades 3/4: 1%), increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, dysgeusia, dyspepsia, dysphagia, gastric ulcer, gastroenteritis, gastrointestinal hemorrhage, gastrointestinal inflammation (upper), gastrointestinal motility disorder (10%), intestinal obstruction, oral discomfort (10%), rectal pain, upper abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression, disorder of hemostatic components of blood, granulocytopenia (grades 3/4: ≤2%), hemorrhage, leukopenia, lymphedema, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, cholestatic hepatitis, hepatic fibrosis, hepatitis, increased serum alanine aminotransferase (grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection, sepsis, viral infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, balance impairment, confusion, depression, dizziness, dysarthria, dysphasia, encephalopathy, headache, insomnia, lethargy (10%), mood changes, myasthenia, peripheral sensory neuropathy (10%), tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain (10%), limb pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, keratoconjunctivitis, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, cough, epistaxis, flu-like symptoms, pharyngeal disease, pneumonia, respiratory distress</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fibrosis, radiation recall phenomenon</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Dyhl-Polk 2020), angina pectoris (Dyhl-Polk 2020), cardiac arrhythmia (Dyhl-Polk 2020), cardiomyopathy (Dyhl-Polk 2020), ECG changes (Dyhl-Polk 2020), heart failure (Dyhl-Polk 2020), ischemic heart disease (Dyhl-Polk 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cutaneous lupus erythematosus (Rocha 2019), Stevens-Johnson syndrome (Karthikeyan 2022), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Necrotizing enterocolitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Leukoencephalopathy (Yoshimura 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal disease (including keratitis), lacrimal stenosis</p></div>
<div class="block coi drugH1Div" id="F145123"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to capecitabine, fluorouracil, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Known complete absence of dihydropyrimidine dehydrogenase (DPD) activity; concomitant administration with sorivudine or chemically related analogues (eg, brivudine).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F145105"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Grade 3 and 4 hyperbilirubinemia have been observed in patients with and without hepatic metastases at baseline (median onset: 64 days). Transaminase and alkaline phosphatase elevations have also been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Dehydration may occur, resulting in acute kidney failure (may be fatal); concomitant use with nephrotoxic agents and baseline kidney dysfunction may increase the risk.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluorouracil/leucovorin (FU/LV): In patients with colorectal cancer, treatment with capecitabine immediately following 6 weeks of FU/LV therapy has been associated with an increased incidence of grade ≥3 toxicity, when compared to patients receiving the reverse sequence, capecitabine (two 3-week courses) followed by FU/LV (Hennig 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• Proton pump inhibitors: Concomitant use of proton pump inhibitors (PPIs) and capecitabine may alter capecitabine dissolution and absorption due to higher gastric pH levels. Secondary analysis of a large, phase 3 study comparing capecitabine and oxaliplatin with or without lapatinib for the treatment of gastroesophageal cancer showed decreased overall survival in patients who received concurrent PPIs (Chu 2017). Similar concern was raised by a retrospective evaluation of capecitabine monotherapy for early-stage colorectal cancer that found worse relapse-free survival in patients receiving a concurrent PPI (Sun 2016). In contrast, a systematic review (Lin 2022) found similar survival among patients with colorectal cancer treated with capecitabine-based regimens with or without a concurrent PPI. Although disease progression was more common among patients with early-stage disease receiving capecitabine monotherapy and a concurrent PPI, there was no difference in all-cause mortality and PPI use did not affect survival among patients receiving capecitabine combination therapy. Similarly, a retrospective evaluation of patients receiving capecitabine with concomitant radiation as neoadjuvant treatment for early-stage rectal cancer found no adverse pathologic or oncologic outcome based on PPI use (Menon 2021). Consider avoiding PPIs (if possible) in patients receiving capecitabine and routinely assess need for continued PPI use with concurrent capecitabine. Potential drug interaction may be more clinically relevant with capecitabine monotherapy. Use of other acid-suppressing medications (eg, H2 antagonists or antacids) may provide sufficient relief of acid reflux symptoms among PPI users and can be more effectively dose-spaced with capecitabine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dihydropyrimidine dehydrogenase deficiency: Patients with certain homozygous or compound heterozygous mutations of the dihydropyrimidine dehydrogenase (DPD) gene <i>(DPYD)</i> are at increased risk for acute early-onset (potentially severe, life-threatening, or fatal) toxicity due to total or near total absence of DPD activity. Toxicity may include mucositis/stomatitis, diarrhea, neutropenia, and neurotoxicity. Capecitabine is not recommended in patients known to have certain homozygous or compound heterozygous <i>DPYD </i>variants that result in complete DPD deficiency. Patients with partial DPD activity are also at risk for severe, life-threatening, or fatal toxicity. May require therapy interruption, reduced doses, and/or permanent discontinuation, depending on the onset, duration, and severity of toxicity observed. No capecitabine dose has been shown to be safe in patients with complete DPD deficiency; data are insufficient to recommend a dose in patients with partial DPD activity according to the prescribing information. The Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group both offer guidance for capecitabine dosing in patients with known reduced DPD activity (CPIC [Amstutz 2018], DPWG [Lunenburg 2020]). Consider testing for genetic variants of <i>DPYD </i>prior to capecitabine initiation to reduce the risk of serious adverse reactions if the patient’s clinical status permits and based on clinical judgement. Serious adverse reactions may still occur even if <i>DPYD </i>variants are not identified.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Older adults experienced increased GI toxicity (compared to younger patients). Deaths due to severe enterocolitis, diarrhea, and dehydration have been reported in older adults receiving fluorouracil/leucovorin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluoropyrimidine overdose: Uridine triacetate has been studied in cases of fluoropyrimidine overdose. In a clinical study of 98 patients who received uridine triacetate for fluorouracil toxicity (due to overdose, accidental capecitabine ingestion, or possible DPD deficiency), 96 patients recovered fully (Bamat 2013). Of 17 patients receiving uridine triacetate beginning within 8 to 96 hours after fluorouracil overdose, all patients fully recovered (von Borstel 2009). An additional case report describes accidental capecitabine ingestion by a 22-month-old child; uridine triacetate was initiated approximately 7 hours after exposure. The patient received uridine triacetate every 6 hours for a total of 20 doses through nasogastric tube administration; he was asymptomatic throughout his course and was discharged with normal laboratory values (Kanie 2011). Refer to Uridine Triacetate monograph.</p></div>
<div class="block foc drugH1Div" id="F145116"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeloda: 150 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F145101"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F145125"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Capecitabine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $3.30 - $11.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $6.50 - $39.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Xeloda Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $16.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $54.22</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866184"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeloda: 150 mg [DSC], 500 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 500 mg</p></div>
<div class="block adm drugH1Div" id="F145120"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer doses at approximately the same times each day, ~12 hours apart. Administer with water within 30 minutes after a meal. Swallow tablets whole; do not cut, chew, or crush. If a dose is missed or vomited, continue with the next scheduled dose; do not administer an additional dose.</p></div>
<div class="block hazard drugH1Div" id="F49130942"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F145119"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Monotherapy: Treatment of advanced or metastatic breast cancer (as a single agent) if an anthracycline- or taxane-containing chemotherapy is not indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">Combination therapy: Treatment of advanced or metastatic breast cancer (in combination with docetaxel) after disease progression on a prior anthracycline-containing regimen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment of stage 3 colon cancer, either as a single agent or as a component of a combination chemotherapy regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">Perioperative treatment of locally advanced rectal cancer in adults, as a component of chemoradiotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of unresectable or metastatic colorectal cancer, either as a single agent or as a component of a combination chemotherapy regimen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric, esophageal, or gastroesophageal junction cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer in adults, as a component of a combination chemotherapy regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in adults who have not received prior treatment for metastatic disease, as a component of a combination regimen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, adjuvant therapy:</b> Adjuvant treatment of pancreatic adenocarcinoma in adults, as a component of a combination chemotherapy regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Guideline recommendations: </i>According to American Society of Clinical Oncology (ASCO) guidelines for potentially curable pancreatic cancer, while first-line adjuvant therapy with another regimen is preferred, capecitabine (in combination with gemcitabine) is an alternate adjuvant therapy option (in the absence of contraindications) if toxicity or tolerance are concerns with the preferred therapy (ASCO [Khorana 2019]).</p></div>
<div class="block off-label drugH1Div" id="F25475318"><span class="drugH1">Use: Off-Label: Adult</span><p>Anal carcinoma; Biliary tract cancer, adjuvant therapy; Biliary tract cancers, advanced; Breast cancer, adjuvant therapy, triple-negative, with residual disease after neoadjuvant therapy and surgery; Gastric cancer, adjuvant treatment; Head and neck cancer: Nasopharyngeal carcinoma, locally advanced; Head and neck cancer, squamous cell, recurrent or metastatic; palliative treatment; Neuroendocrine tumors: GI/carcinoid, refractory; Neuroendocrine tumors: Pancreatic/islet cell, metastatic or unresectable; Ovarian, fallopian tube, or peritoneal cancers, refractory; Pancreatic cancer, locally advanced or metastatic; Small bowel adenocarcinoma, advanced unresectable or metastatic; Thymic malignancies, refractory; Unknown primary cancer</p></div>
<div class="block mst drugH1Div" id="F2704106"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Capecitabine may be confused with cabozantinib, capmatinib</p>
<p style="text-indent:-2em;margin-left:4em;">Xeloda may be confused with Xenical, Xpovio</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9837645"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP2C9 (weak)</p></div>
<div class="block dri drugH1Div" id="F2706932"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: May decrease serum concentrations of the active metabolite(s) of Fluorouracil Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: May enhance the nephrotoxic effect of Capecitabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Fluorouracil Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CARBOplatin: May enhance the nephrotoxic effect of Capecitabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cedazuridine: May increase the serum concentration of Cytidine Deaminase Substrates.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CISplatin: May enhance the nephrotoxic effect of Capecitabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Fluorouracil Products may enhance the myelosuppressive effect of CloZAPine. CloZAPine may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: Fluorouracil Products may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Fluorouracil Products may enhance the myelosuppressive effect of Fexinidazole. Fexinidazole may enhance the QTc-prolonging effect of Fluorouracil Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: May enhance the QTc-prolonging effect of other Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Folic Acid: May enhance the adverse/toxic effect of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C9 Inhibitors (Weak) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gimeracil: May increase the serum concentration of Fluorouracil Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Capecitabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferons (Alfa): May increase the serum concentration of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: May enhance the nephrotoxic effect of Capecitabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leucovorin Calcium-Levoleucovorin: May enhance the adverse/toxic effect of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the nephrotoxic effect of Capecitabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May increase the serum concentration of Fluorouracil Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxaliplatin: May enhance the nephrotoxic effect of Capecitabine. Oxaliplatin may enhance the neurotoxic (peripheral) effect of Capecitabine. Oxaliplatin may enhance the QTc-prolonging effect of Capecitabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): Fluorouracil Products may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): Fluorouracil Products may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telotristat Ethyl: May decrease serum concentrations of the active metabolite(s) of Capecitabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: CYP2C9 Inhibitors (Weak) may increase the serum concentration of TOLBUTamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Fluorouracil Products may increase the serum concentration of Vitamin K Antagonists.  Management: Monitor INR and for signs/symptoms of bleeding closely when a fluorouracil product is combined with a vitamin K antagonist (eg, warfarin). Anticoagulant dose adjustment will likely be necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F145137"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food reduced the rate and extent of absorption of capecitabine. Following administration of a meal (breakfast; medium-rich in fat and carbohydrates), the mean capecitabine C<sub>max</sub> and AUC<sub>0-INF</sub> were reduced by 60% and 34%, respectively, and the mean fluorouracil C<sub>max</sub> and AUC<sub>0-INF</sub> were reduced by 37% and 12%, respectively. The time to peak of both capecitabine and fluorouracil was delayed by 1.5 hours. Management: Administer within 30 minutes after a meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F53539384"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation. Patients who could become pregnant should use effective contraception during treatment and for 6 months after the last dose of capecitabine. Patients with partners who could become pregnant should use effective contraception during treatment and for 3 months after the last capecitabine dose.</p></div>
<div class="block pri drugH1Div" id="F145126"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to capecitabine may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of capecitabine during pregnancy are limited (Cardonick 2010; Castellanos 2020; Sharma 2016).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology (ESMO) has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach. In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery (for adequate maternal and fetal bone marrow recovery), and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F145127"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if capecitabine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 1 week after the last capecitabine dose. Other guidance suggests waiting at least 24 hours after the last dose of capecitabine and feeding with breast milk; however, actual recommendations should be individualized. Patients may maintain milk supply by expressing during treatment; however, milk supply is expected to be decreased by systemic chemotherapy (ABM [Johnson 2020]).</p></div>
<div class="block mop drugH1Div" id="F145114"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential (at baseline and prior to each cycle), hepatic function (as clinically indicated; more frequently if hepatotoxicity occurs), and kidney function (at baseline and as clinically indicated). Monitor INR closely/more frequently if receiving a concomitant vitamin K antagonist. Evaluate pregnancy status prior to treatment initiation (in patients who could become pregnant). Monitor hydration status at baseline and as clinically indicated. Monitor for signs/symptoms of diarrhea, dehydration, hand-foot syndrome, new or worsening serious skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), stomatitis, hepatotoxicity, nephrotoxicity, and cardiotoxicity. Promptly evaluate any symptoms suggestive of cardiotoxicity. Consider monitoring ECG in patients on concomitant QT-prolonging medications. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider testing for genetic variants of the dihydropyrimidine dehydrogenase gene <i>(DPYD) </i>prior to capecitabine initiation.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Obtain baseline blood pressure, electrocardiogram, lipid profile, hemoglobin A1c, and assess cardiovascular risk score; obtain a baseline echocardiography (transthoracic preferred) in patients with a history of symptomatic cardiovascular disease (ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F145104"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Capecitabine is a prodrug of fluorouracil. It undergoes hydrolysis in the liver and tissues to form fluorouracil which is the active moiety. Fluorouracil is a fluorinated pyrimidine antimetabolite that inhibits thymidylate synthetase, blocking the methylation of deoxyuridylic acid to thymidylic acid, interfering with DNA, and to a lesser degree, RNA synthesis. Fluorouracil appears to be phase specific for the G<sub>1</sub> and S phases of the cell cycle.</p></div>
<div class="block phk drugH1Div" id="F145122"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and extensive (rate and extent reduced by food).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;60%; ~35% to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Inactive metabolites: 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine.</p>
<p style="text-indent:-2em;margin-left:4em;">Tissue: Enzymatically metabolized to fluorouracil, which is then metabolized to active metabolites, 5-fluoroxyuridine monophosphate (F-UMP) and 5-5-fluoro-2’-deoxyuridine-5’-O-monophosphate (F-dUMP).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~0.75 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Capecitabine: 1.5 hours; Fluorouracil: 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (96%, 57% as α-fluoro-β-alanine; &lt;3% as unchanged drug); feces (&lt;3%).</p></div>
<div class="block phksp drugH1Div" id="F51154189"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In moderate to severe kidney function impairment, there is increased exposure to inactive metabolites (FBAL and 5’-DFUR) and a 25% increase in exposure to capecitabine.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In mild to moderate hepatic dysfunction due to liver metastases, capecitabine AUC<sub>0-INF</sub> and C<sub>max</sub> increased 60%; 5-FU was not affected. The effect of severe hepatic dysfunction is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In a study of patients ranging from ages 27 to 86 years, age had no significant influence on the pharmacokinetics of 5’-DFUR, 5-FU; a 20% increase in age resulted in a 15% increase in the AUC of alpha-fluoro-beta-alanine (FBAL).</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Following oral administration of 825 mg/m<sup>2</sup> capecitabine twice daily for 14 days, Japanese patients (n = 18) had about 36% lower C<sub>max</sub> and 24% lower AUC for capecitabine compared to White patients (n = 22). Japanese patients had also about 25% lower C<sub>max</sub> and 34% lower AUC for alpha-fluoro-beta-alanine than White patients, although the clinical significance of these differences is unknown.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F145129"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dirogit | Xeloda</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bodabina | Capecinova | Capecit | Capecitabina glenmark | Capecitabina gobbi | Capecitabina gp pharma | Capecitabina ima | Capecitabina Techsphere | Capecitabina varifarma | Capectan | Capefas | Capexan | Capicitabina filax | Captech | Categor | Catepen | Derebel | Recaz | Xeloda | Xitabin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Capecel | Capecitabin accord | Capecitabin medac | Capecitabin teva | Capecitabine fresenius kabi | Capecitabine sandoz | Capecitabine stada | Xeloda</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine actavis | Capecitabine alphapharm | Capecitabine an | Capecitabine apotex | Capecitabine drla | Capecitabine gh | Capecitabine myx | Capecitabine sandoz | Xelabine | Xelocitabine | Xeloda</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cabita | Capcitab | Capecitin | Tysinor | Xeloda</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine eg | Capecitabine fresenius kabi | Capecitabine medac | Capecitabine sun | Capecitabine teva | Xeloda</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Capetero</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine actavis | Capecitabine sandoz | Capecitabine Zentiva | Capeda | Coloxet | Ecansya | Xalvobin | Xeloda</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Capecare | Capecitabina | Capeliv | Capzat | Coama | Corretal | Xeloda</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Capecitabin accord | Capecitabin actavis | Capecitabin fresenius | Capecitabin helvepharm | Capecitabin sandoz | Capecitabin teva | Capecitabin zentiva | Xeloda</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Capetero | Xeloda</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Capecitabina | Categor | Corretal | Xeloda</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai bin | Shou fu | Xeloda | Xi luo da</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Capec | Capecitabina | Capecital | Capegard | Capetabin | Capexel | Capiibine | Caxeta | Cepectin | Citabibex | Corretal | Kapixa | Kaxel | Kaxel 500 mg | Kpbyn | Nabticen | Pacsita | Xeloda</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Capecitabin actavis | Capecitabine accord | Capecitabine fresenius kabi | Capecitabine glenmark | Capecitabine medac | Capecitabine medico uno | Capecitabine mylan | Capecitabine pharmagen | Capecitabine sandoz | Capecitabine teva | Coloxet | Ecansya | Xeloda</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Capecitabin accord | Capecitabin actavis | Capecitabin al | Capecitabin beta | Capecitabin biomo | Capecitabin glenmark | Capecitabin hexal | Capecitabin hormosan | Capecitabin medac | Capecitabin onkovis | Capecitabin sun | Capecitabin teva | Capecitabin zentiva | Ecansya | Xeloda</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Capecitabina | Capecitabina lam | Capefas | Captiva | Xeloda | Xenevia</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Capec | Capecit | Capecitabina | Capecitabina kemex | Capecitabina nifa | Capecital | Capefas | Xeloda | Xenevia</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine teva | Capecitabine Zentiva | Xeloda</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine pharmacare | Xeloda</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Capecitabina accord | Capecitabina actavis | Capecitabina combino pharm | Capecitabina fresenius kabi | Capecitabina glenmark | Capecitabina kern pharma | Capecitabina normon | Capecitabina sandoz | Capecitabina teva | Xelcip | Xeloda</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Capetero | Capxcel | Xeloda</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Capecitabin actavis | Capecitabine accord | Capecitabine medac | Capecitabine orion | Capecitabine teva | Ecansya | Xeloda</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine actavis | Capecitabine arrow | Capecitabine biogaran | Capecitabine cristers | Capecitabine eg | Capecitabine mylan | Capecitabine sandoz | Capecitabine teva | Capecitabine Zentiva | Xeloda</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine actavis | Capecitabine dr reddys | Capecitabine medac | Capecitabine mylan | Capecitabine sun | Capecitabine Zentiva | Xeloda</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine teva | Capecitabine/fresenius kabi | Capecitabine/mylan | Capibine | Preveloda | Xelazor | Xeloda | Zerectum</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine sandoz | Capecitabine teva | Xeloda</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cansata | Capecitabine accord | Kapecitabin JGL | Kapecitabin sandoz | Kapetral | Xalvobin | Xelcip | Xeloda</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Capecitabin actavis | Capecitabin sandoz | Capecitabine accord | Capecitabine teva | Coloxet | Ecansya | Xalvobin | Xeloda</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Binecap | Taceral | Xeloda</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine actavis | Capecitabine sandoz | Ecansya | Xeloda</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Xeloda</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">C bine | Capcel | Capecad | Capecite | Capegard | Capehope | Capeta | Capetaz | Capeway | Capibine | Capiibine | Capostat | Captabin | Capxcel | Caxeta | Citabin | Distamine | Glancap | K cap | Pro 5 | PV Capebine | Relicitabine | Xabine | Xecap | Xeloda | Xortib | Zocitab</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Xeloda</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Capecitabina accord | Capecitabina actavis | Capecitabina crinos | Capecitabina fresenius kabi | Capecitabina medac | Capecitabina mylan | Capecitabina sandoz | Capecitabina teva | Capecitabina zentiva | Xeloda</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cabitex | Dirogit</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine jg | Capecitabine nichiiko | Capecitabine nk | Capecitabine towa | Xeloda</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bdocin | Capecitabine sandoz | Capemax | Capetero | Capxcel | Caxeta | Glocapx | Naprocap | Pacsita | Tysinor | Xeloda</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Capebin | Captabin | Xalvobin | Xelcatabine | Xelobig | Xelocan | Xeloda</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Xeloda</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aceda | Capacer | Capecitabine biogaran | Capeda | Dirogit | Xeloda</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Actabi | Capecitabine accord | Capecitabine medac | Capecitabine sandoz | Capecitabine teva | Capecitabine Zentiva | Ecansya | Xalvobin | Xelcip | Xeloda</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine actavis | Capecitabine eg | Capecitabine teva | Xeloda</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine medac | Capecitabine sandoz | Capecitabine teva | Capecitabine Zentiva | Ecansya | Vopecidex | Xeloda</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Xeloda | Xepine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Capecitabina | Categor | Kpbyn | Plexoda | Simcaxeta | Skemca | Xeloda</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Intacape | Xeloda</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Bdocin | Capetero | Glocapx | Sjs capecitabine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine actavis | Capecitabine cf | Capecitabine mylan | Capecitabine sandoz | Capecitabine sun | Capecitabine teva | Xeloda</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine accord | Capecitabine actavis | Xeloda</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Brinov | Capecitabine winthrop | Capercit | Xeloda</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Betrapone | Capecitabina | Corretal | Emcap | Xeloda</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Capetero 500 | Capnorm | Caponko | Capvex | Caxeta | Celabin | Cetagen 500 | Naprocap | Xeloda | Xeltabine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Capcita | Capegard | Relicitabine | Xelobig | Xelocel | Xeloda | Zenatibin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cantaloda | Capecitabine accord | Capecitabine actavis | Capecitabine adamed | Capecitabine glenmark | Capecitabine medac | Capecitabine Polpharma | Capecitabine teva | Capecitabine Zentiva | Capecitalox | Ecansya | Symloda | Vopecidex | Xalvobin | Xeloda</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Xeloda</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Capecitabina accord | Capecitabina actavis | Capecitabina farmoz | Capecitabina fresenius kabi | Capecitabina medac | Capecitabina sandoz | Capecitabina teva | Capecitabina zentiva | Xeloda</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Betrapone | Capebina | Capecit | Capecitabina bioteng | Capecitabina demotek | Capecitabina gebina | Capecitabina imedic | Capecitabina intas | Capecitabina kemex | Capecitabina khairi | Capecitabina libra | Capecitabina prosalud | Capecitabina tuteur | Capecitabina vmg | Capectan | Capefas | Xeloda | Xenevia</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Xeloda</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Arxeda | Capecitabina actavis | Capecitabina fresenius kabi | Capecitabina glenmark | Capecitabina zentiva | Capecitabine accord | Cerex | Coloxet | Ecansya | Xalvobin | Xeloda</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cabecin | Capametin fs | Capecitabin | Capecitabine tl | Capecitover | Tutabin | Xalvobin | Xeloda</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine spc | Catabina | Xeloda</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Capecitabin actavis | Capecitabin stada | Capecitabine accord | Capecitabine fresenius kabi | Capecitabine medac | Capecitabine orion | Capecitabine sandoz | Capecitabine sun | Capecitabine teva | Ecansya | Xalvobin | Xeloda</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Intacape | Xeloda</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ecansya | Kapecitabin accord | Kapecitabin sandoz | Kapecitabin teva | Xeloda</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Capecitabin sandoz | Capecitabine accord | Capecitabine actavis | Capecitabine cande | Capecitabine fresenius kabi | Capecitabine glenmark | Capecitabine medac | Capecitabine pharmacenter | Capecitabine stada | Capecitabine teva | Capecitabine Zentiva | Capecitalox | Coloxet | Ecansya | Xeloda</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine alvogen | Intacape | Xeloda</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine mylan | Capecitabine Zentiva | Dirogit | Xeloda</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Capetabin | Kapeda | Xeloda | Xeltabin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine Zentiva | Kapetral | Xeloda</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Apsibin | Capecibex | Capecitabine KRKA | Ental | Kapevista | Xeloda</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Capetero | Capxcel</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Capebina | Capecitabina sandoz | Capefas | Citabin | Xeloda</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Capsy</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Relotabin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Binecap | Capecitabine cipla | Capecitabine Specpharm | Capeloda | Capexa | Captero | Pecaset | Tanicep | Xeloda | Zelbeen</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Capecitabine sandoz | Citabin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Xeloda</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HazardousDrugs.2020">
<a name="HazardousDrugs.2020"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29152729">
<a name="29152729"></a>Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. <i>Clin Pharmacol Ther</i>. 2018;103(2):210-216. doi:10.1002/cpt.911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/29152729/pubmed" id="29152729" target="_blank">29152729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23122784">
<a name="23122784"></a>Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. <i>Lancet Oncol</i>. 2013;14(1):64-71. doi:10.1016/S1470-2045(12)70432-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/23122784/pubmed" id="23122784" target="_blank">23122784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16937105">
<a name="16937105"></a>Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?<i> Cancer Chemother Pharmacol</i>. 2007;59(5):637-642. doi:10.1007/s00280-006-0306-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/16937105/pubmed" id="16937105" target="_blank">16937105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15710946">
<a name="15710946"></a>Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. <i>J Clin Oncol</i>. 2005;23(10):2155-2161. doi:10.1200/JCO.2005.02.167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/15710946/pubmed" id="15710946" target="_blank">15710946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247216">
<a name="27247216"></a>Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2016;34(22):2654-2668. doi:10.1200/JCO.2016.67.5561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/27247216/pubmed" id="27247216" target="_blank">27247216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bamat.2013">
<a name="Bamat.2013"></a>Bamat MK, Tremmel R, von Borstel R, et al. Clinical experience with uridine triacetate for 5-FU overexposure: an update [abstract e20592 from 2013 ASCO Annual Meeting]. <i>J Clin Oncol</i>. 2013;31(18s):e20592.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22226517">
<a name="22226517"></a>Bang YJ, Kim YW, Yang HK, et al; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. <i>Lancet</i>. 2012;379(9813):315-321. doi:10.1016/S0140-6736(11)61873-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/22226517/pubmed" id="22226517" target="_blank">22226517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20728210">
<a name="20728210"></a>Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appearing in <i>Lancet</i>. 2010;376(9749):1302]. <i>Lancet</i>. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/20728210/pubmed" id="20728210" target="_blank">20728210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17679724">
<a name="17679724"></a>Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. <i>J Clin Oncol</i>. 2007;25(25):3853-3858. doi:10.1200/JCO.2007.11.9776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/17679724/pubmed" id="17679724" target="_blank">17679724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25964250">
<a name="25964250"></a>Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiosarcoma and gallbladder carcinoma. <i>J Clin Oncol</i>. 2015;33(24):2617‐2622. doi:10.1200/JCO.2014.60.2219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/25964250/pubmed" id="25964250" target="_blank">25964250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33741260">
<a name="33741260"></a>Bryson E, Sakach E, Patel U, et al. Safety and efficacy of 7 days on/7 days off versus 14 days on/7 days off schedules of capecitabine in patients with metastatic colorectal cancer: a retrospective review. <i>Clin Colorectal Cancer</i>. 2021;20(2):153-160. doi:10.1016/j.clcc.2020.12.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/33741260/pubmed" id="33741260" target="_blank">33741260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19745695">
<a name="19745695"></a>Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. <i>Am J Clin Oncol</i>. 2010;33(3):221-228. doi:10.1097/COC.0b013e3181a44ca9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/19745695/pubmed" id="19745695" target="_blank">19745695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773165">
<a name="11773165"></a>Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. <i>J Clin Oncol</i>. 2002;20(1):160-164. doi:10.1200/JCO.2002.20.1.160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/11773165/pubmed" id="11773165" target="_blank">11773165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18421053">
<a name="18421053"></a>Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. <i>J Clin Oncol</i>. 2008;26(12):2006-2012. doi:10.1200/JCO.2007.14.9898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/18421053/pubmed" id="18421053" target="_blank">18421053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15169795">
<a name="15169795"></a>Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. <i>J Clin Oncol</i>. 2004;22(11):2084-2091. doi:10.1200/JCO.2004.11.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/15169795/pubmed" id="15169795" target="_blank">15169795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12056707">
<a name="12056707"></a>Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. <i>Ann Oncol</i>. 2002;13(4):566-575. doi:10.1093/annonc/mdf089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/12056707/pubmed" id="12056707" target="_blank">12056707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32712180">
<a name="32712180"></a>Castellanos MI, Childress KJ, Ramirez M, et al. Fetal exposure to capecitabine and temozolomide during the first trimester: a case report. <i>J Gynecol Obstet Hum Reprod</i>. Published online July 23, 2020. doi:10.1016/j.jogoh.2020.101881<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/32712180/pubmed" id="32712180" target="_blank">32712180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23988873">
<a name="23988873"></a>Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. <i>Clin Pharmacol Ther</i>. 2013;94(6):640-645. doi:10.1038/clpt.2013.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/23988873/pubmed" id="23988873" target="_blank">23988873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33452614">
<a name="33452614"></a>Celik E, Samanci NS, Karadag M, Demirci NS, Demirelli FH, Ozguroglu M. The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer. <i>Med Oncol</i>. 2021;38(1):11. doi:10.1007/s12032-021-01457-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/33452614/pubmed" id="33452614" target="_blank">33452614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33405943">
<a name="33405943"></a>Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline.<i> J Clin Oncol</i>. 2021b;39(7):840-859. doi:10.1200/JCO.20.03237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/33405943/pubmed" id="33405943" target="_blank">33405943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34111416">
<a name="34111416"></a>Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. <i>Lancet</i>. 2021a;398(10297):303-313. doi:10.1016/S0140-6736(21)01123-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/34111416/pubmed" id="34111416" target="_blank">34111416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27737436">
<a name="27737436"></a>Chu MP, Hecht JR, Slamon D, et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. <i>JAMA Oncol</i>. 2017;3(6):767-773. doi:10.1001/jamaoncol.2016.3358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/27737436/pubmed" id="27737436" target="_blank">27737436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19858379">
<a name="19858379"></a>Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. <i>J Clin Oncol.</i> 2009;27(33):5513-5518. doi:10.1200/JCO.2009.24.2446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/19858379/pubmed" id="19858379" target="_blank">19858379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18172173">
<a name="18172173"></a>Cunningham D, Starling N, Rao S, et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. <i>N Engl J Med</i>. 2008;358(1):36-46. doi:10.1056/NEJMoa073149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/18172173/pubmed" id="18172173" target="_blank">18172173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22184401">
<a name="22184401"></a>Dahan L, Ciccolini J, Evrard A, et al. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications. <i>J Clin Oncol</i>. 2012;30(4):e41-e44. doi:10.1200/JCO.2011.37.9289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/22184401/pubmed" id="22184401" target="_blank">22184401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28520372">
<a name="28520372"></a>Dean L, Kane M. Capecitabine Therapy and <i>DPYD</i> Genotype. 2016 [updated 2020 Nov 2]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/28520372/pubmed" id="28520372" target="_blank">28520372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29787356">
<a name="29787356"></a>Denduluri N, Chavez-MacGregor M, Telli ML, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO Clinical Practice Guideline Focused Update. <i>J Clin Oncol</i>. 2018;36(23):2433-2443. doi:10.1200/JCO.2018.78.8604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/29787356/pubmed" id="29787356" target="_blank">29787356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34609922">
<a name="34609922"></a>Deneken-Hernandez Z, Cherem-Kibrit M, Gutiérrez-Andrade L, Rodríguez-Gutiérrez G, Colmenero-Mercado JO. Capecitabine induced fingerprint loss: Case report and review of the literature. <i>J Oncol Pharm Pract</i>. 2022;28(2):495-499. doi:10.1177/10781552211045009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/34609922/pubmed" id="34609922" target="_blank">34609922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31931649">
<a name="31931649"></a>Dyhl-Polk A, Vaage-Nilsen M, Schou M, et al. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. <i>Acta Oncol</i>. 2020;59(4):475-483. doi:10.1080/0284186X.2019.1711164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31931649/pubmed" id="31931649" target="_blank">31931649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16131047">
<a name="16131047"></a>Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. <i>Oncology (Williston Park)</i>. 2005;19(8):1057-1069.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/16131047/pubmed" id="16131047" target="_blank">16131047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17440727">
<a name="17440727"></a>Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis [published correction appearing in <i>Cancer Chemother Pharmacol</i>. 2008 Jan;61(1):177]. <i>Cancer Chemother Pharmacol</i>. 2008;61(1):167-175. doi:10.1007/s00280-007-0473-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/17440727/pubmed" id="17440727" target="_blank">17440727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14962720">
<a name="14962720"></a>Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. <i>Eur J Cancer.</i> 2004;40(4):536-542. doi:10.1016/j.ejca.2003.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/14962720/pubmed" id="14962720" target="_blank">14962720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17192538">
<a name="17192538"></a>Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [published correction appearing in <i>N Engl J Med</i>. 2007;356(14):1487]. <i>N Engl J Med</i>. 2006;355(26):2733-2743. doi:10.1056/NEJMoa064320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/17192538/pubmed" id="17192538" target="_blank">17192538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17022868">
<a name="17022868"></a>Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. <i>J Oncol Pharm Pract</i>. 2006;12(3):131-141. doi:10.1177/1078155206069242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/17022868/pubmed" id="17022868" target="_blank">17022868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33552791">
<a name="33552791"></a>Habib MB, Hanafi I, Al Zoubi M, Bdeir Z, Yassin MA. Severe and late acute liver injury induced by capecitabine. <i>Cureus</i>. 2021;13(1):e12477. doi:10.7759/cureus.12477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/33552791/pubmed" id="33552791" target="_blank">33552791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20209610">
<a name="20209610"></a>Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. <i>Cancer</i>. 2010;116(10):2448-54. doi:10.1002/cncr.25029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/20209610/pubmed" id="20209610" target="_blank">20209610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32675783">
<a name="32675783"></a>Halfdanarson TR, Strosberg JR, Tang L, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. <i>Pancreas</i>. 2020;49(7):863-881. doi:10.1097/MPA.0000000000001597<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/32675783/pubmed" id="32675783" target="_blank">32675783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33983395">
<a name="33983395"></a>Hall PS, Swinson D, Cairns DA, et al. Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. <i>JAMA Oncol.</i> 2021;7(6):869-877. doi:10.1001/jamaoncol.2021.0848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/33983395/pubmed" id="33983395" target="_blank">33983395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18445840">
<a name="18445840"></a>Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. <i>J Clin Oncol</i>. 2008;26(13):2118-23. doi:10.1200/JCO.2007.15.2090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/18445840/pubmed" id="18445840" target="_blank">18445840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21383294">
<a name="21383294"></a>Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. <i>J Clin Oncol</i>. 2011;29(11):1465-1471. doi:10.1200/JCO.2010.33.6297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/21383294/pubmed" id="21383294" target="_blank">21383294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18612156">
<a name="18612156"></a>Hennig IM, Naik JD, Brown S, et al. Severe sequence-specific toxicity when capecitabine is given after fluorouracil and leucovorin. <i>J Clin Oncol</i>. 2008;26(20):3411-3417. doi:10.1200/JCO.2007.15.9426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/18612156/pubmed" id="18612156" target="_blank">18612156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15342618">
<a name="15342618"></a>Heo YS, Chang HM, Kim TW, et al. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. <i>J Clin Pharmacol</i>. 2004;44(10):1166-1172. doi:10.1177/0091270004268321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/15342618/pubmed" id="15342618" target="_blank">15342618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18448556">
<a name="18448556"></a>Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. <i>Oncologist</i>. 2008;13(4):415-23. doi:10.1634/theoncologist.2007-0252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/18448556/pubmed" id="18448556" target="_blank">18448556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11304782">
<a name="11304782"></a>Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. <i>J Clin Oncol</i>. 2001;19(8):2282-92. doi:10.1200/JCO.2001.19.8.2282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/11304782/pubmed" id="11304782" target="_blank">11304782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22503032">
<a name="22503032"></a>Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. <i>Lancet Oncol</i>. 2012;13(6):579-588. doi:10.1016/S1470-2045(12)70116-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/22503032/pubmed" id="22503032" target="_blank">22503032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15319239">
<a name="15319239"></a>Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. <i>Ann Oncol</i>. 2004;15(9):1344-1347. doi:10.1093/annonc/mdh343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/15319239/pubmed" id="15319239" target="_blank">15319239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28066869">
<a name="28066869"></a>Jadhav P, Rogers JE, Shroff R. A case report-Stevens-Johnson syndrome as an adverse effect of capecitabine. <i>J Gastrointest Cancer</i>. 2018;49(3):349-350. doi:10.1007/s12029-016-9916-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/28066869/pubmed" id="28066869" target="_blank">28066869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34102137">
<a name="34102137"></a>Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2021a;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/34102137/pubmed" id="34102137" target="_blank">34102137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34912120">
<a name="34912120"></a>Janjigian YY, Kawazoe A, Yanez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature.</i> 2021b;600(7890):727-730. doi:10.1038/s41586-021-04161-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/34912120/pubmed" id="34912120" target="_blank">34912120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol</i>. 2010;21(7):1395-1403. doi:10.1093/annonc/mdp598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16303863">
<a name="16303863"></a>Jatoi A, Murphy BR, Foster NR, et al; North Central Cancer Treatment Group. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.<i> Ann Oncol.</i> 2006;17(1):29-34. doi:10.1093/annonc/mdj063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/16303863/pubmed" id="16303863" target="_blank">16303863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19235592">
<a name="19235592"></a>Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. <i>Cancer Invest</i>. 2009;27(2):193-200. doi:10.1080/07357900802172093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/19235592/pubmed" id="19235592" target="_blank">19235592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22392964">
<a name="22392964"></a>Jhaveri KD, Flombaum C, Shah M, Latcha S. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR &lt;30 mL/min) and end stage renal disease on hemodialysis. <i>J Oncol Pharm Pract</i>. 2012;18(1):140-147. doi:10.1177/1078155210390255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/22392964/pubmed" id="22392964" target="_blank">22392964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32516007">
<a name="32516007"></a>Johnson HM, Mitchell KB; Academy of Breastfeeding Medicine. ABM clinical protocol #34: breast cancer and breastfeeding. <i>Breastfeed Med</i>. 2020;15(7):429-434. doi:10.1089/bfm.2020.29157.hmj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/32516007/pubmed" id="32516007" target="_blank">32516007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34640443">
<a name="34640443"></a>Jurczyk M, Król M, Midro A, Kurnik-Łucka M, Poniatowski A, Gil K. Cardiotoxicity of fluoropyrimidines: Epidemiology, mechanisms, diagnosis, and management. <i>J Clin Med</i>. 2021;10(19):4426. doi:10.3390/jcm10194426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/34640443/pubmed" id="34640443" target="_blank">34640443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19153121">
<a name="19153121"></a>Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. <i>Ann Oncol</i>. 2009;20(4):666-673. doi:10.1093/annonc/mdn717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/19153121/pubmed" id="19153121" target="_blank">19153121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanie.2011">
<a name="Kanie.2011"></a>Kanie K, Plasencia AA, Dribben W, Tremmel R. Capecitabine [NACCT abstracts]. <i>Clinical Toxicology</i>. 2011;49:515-627.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34162250">
<a name="34162250"></a>Karthikeyan K, Sameera KV, Shaji S, Swetha MAC, Madhu CS. Capecitabine induced Steven-Johnson syndrome: A rare case report. <i>J Oncol Pharm Pract</i>. 2022;28(1):250-254. doi:10.1177/10781552211027945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/34162250/pubmed" id="34162250" target="_blank">34162250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180816">
<a name="31180816"></a>Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2019;37(23):2082-2088. doi:10.1200/JCO.19.00946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31180816/pubmed" id="31180816" target="_blank">31180816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12853355">
<a name="12853355"></a>Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. <i>Ann Oncol</i>. 2003;14(7):1115-1120. doi:10.1093/annonc/mdg281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/12853355/pubmed" id="12853355" target="_blank">12853355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15800324">
<a name="15800324"></a>Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. <i>J Clin Oncol</i>. 2005;23(10):2332-2338. doi:10.1200/JCO.2005.51.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/15800324 /pubmed" id="15800324 " target="_blank">15800324 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21924464">
<a name="21924464"></a>Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. <i>J Allergy Clin Immunol</i>. 2011;128(6):1266-1276.e11. doi:10.1016/j.jaci.2011.08.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/21924464/pubmed" id="21924464" target="_blank">21924464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21275495">
<a name="21275495"></a>Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192. doi:10.1592/phco.31.2.164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/21275495/pubmed" id="21275495" target="_blank">21275495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31382864">
<a name="31382864"></a>Lampropoulou DI, Laschos K, Amylidi AL, et al. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA? <i>J Oncol Pharm Pract</i>. 2020;26(3):747-753. doi:10.1177/1078155219865597<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31382864/pubmed" id="31382864" target="_blank">31382864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32497261">
<a name="32497261"></a>Lee AWM, Ngan RKC, Ng WT, et al. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. <i>Cancer</i>. 2020;126(16):3674-3688. doi:10.1002/cncr.32972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/32497261/pubmed" id="32497261" target="_blank">32497261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16489675">
<a name="16489675"></a>Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. <i>World J Gastroenterol</i>. 2006;12(4):603-607. doi:10.3748/wjg.v12.i4.603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/16489675/pubmed" id="16489675" target="_blank">16489675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17951334">
<a name="17951334"></a>Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. <i>Jpn J Clin Oncol</i>. 2007;37(11):829-835. doi:10.1093/jjco/hym117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/17951334/pubmed" id="17951334" target="_blank">17951334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35641220">
<a name="35641220"></a>Lestuzzi C, Stolfo D, De Paoli A, et al. Cardiotoxicity from capecitabine chemotherapy: Prospective study of incidence at rest and during physical exercise. <i>Oncologist</i>. 2022;27(2):e158-e167. doi:10.1093/oncolo/oyab035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/35641220/pubmed" id="35641220" target="_blank">35641220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26755510">
<a name="26755510"></a>Lichtman SM, Cirrincione CT, Hurria A, et al. Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: alliance A171201, an ancillary study of CALGB/CTSU 49907. <i>J Clin Oncol</i>. 2016;34(7):699-705. doi:10.1200/JCO.2015.62.6341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/26755510/pubmed" id="26755510" target="_blank">26755510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36578549">
<a name="36578549"></a>Lin WY, Wang SS, Kang YN, et al. Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysis. <i>Front Pharmacol.</i> 2022;13:1048980. doi:10.3389/fphar.2022.1048980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/36578549/pubmed" id="36578549" target="_blank">36578549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27631426">
<a name="27631426"></a>Lou Y, Wang Q, Zheng J, et al. Possible pathways of capecitabine-induced hand-foot syndrome. <i>Chem Res Toxicol</i>. 2016;29(10):1591-1601. doi:10.1021/acs.chemrestox.6b00215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/27631426/pubmed" id="27631426" target="_blank">27631426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31745289">
<a name="31745289"></a>Lunenburg CATC, van der Wouden CH, Nijenhuis M, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <i>Eur J Hum Genet</i>. 2020;28(4):508-517. doi:10.1038/s41431-019-0540-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31745289/pubmed" id="31745289" target="_blank">31745289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20485287">
<a name="20485287"></a>Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. <i>Br J Cancer.</i> 2010;102(12):1687-1691. doi:10.1038/sj.bjc.6605697<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/20485287/pubmed" id="20485287" target="_blank">20485287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28564564">
<a name="28564564"></a>Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. <i>N Engl J Med</i>. 2017;376(22):2147-2159. doi:10.1056/NEJMoa1612645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/28564564/pubmed" id="28564564" target="_blank">28564564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11772141">
<a name="11772141"></a>McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. <i>Drugs</i>. 2001;61(15):2309-26. doi:10.2165/00003495-200161150-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/11772141/pubmed" id="11772141" target="_blank">11772141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34269694">
<a name="34269694"></a>Menon A, Abraham AG, Mahfouz M, et al. Concomitant use of proton pump inhibitors with capecitabine based neoadjuvant chemoradiotherapy for locally advanced rectal cancer: Is it safe? <i>Am J Clin Oncol</i>. 2021;44(9):487-494. doi:10.1097/COC.0000000000000850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/34269694/pubmed" id="34269694" target="_blank">34269694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25167226">
<a name="25167226"></a>Meulendijks D, Dewit L, Tomasoa NB, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. <i>Br J Cancer</i> 2014;111(9):1726-1733. doi:10.1038/bjc.2014.467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/25167226/pubmed" id="25167226" target="_blank">25167226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36227615">
<a name="36227615"></a>Miao J, Wang L, Tan SH, et al. Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial. <i>JAMA Oncol.</i> 2022;8(12):1776-1785. doi:10.1001/jamaoncol.2022.4656<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/36227615/pubmed" id="36227615" target="_blank">36227615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22145749">
<a name="22145749"></a>Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. <i>Am J Clin Dermatol</i>. 2012;13(1):49-54. doi:10.2165/11593240-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/22145749/pubmed" id="22145749" target="_blank">22145749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, Ajithkumar T. Management of uncommon chemotherapy-induced emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814. doi:10.1016/S1470-2045(10)70208-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8391384">
<a name="8391384"></a>Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. <i>Cancer Res</i>. 1993;53(13):3028-3033.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/8391384/pubmed" id="8391384" target="_blank">8391384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31825569">
<a name="31825569"></a>Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. <i>N Engl J Med</i>. 2020;382(7):597‐609. doi:10.1056/NEJMoa1914609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31825569/pubmed" id="31825569" target="_blank">31825569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18182984">
<a name="18182984"></a>Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. <i>Br J Cancer</i>. 2008;98(2):309-315. doi:10.1038/sj.bjc.6604178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/18182984 /pubmed" id="18182984 " target="_blank">18182984 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nemecek.1">
<a name="Nemecek.1"></a>Nemecek BD, Hammond DA. <i>Demystifying Drug Dosing in Renal Dysfunction</i>. American Society of Health-System Pharmacists; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28129987">
<a name="28129987"></a>Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.<i> Lancet</i>. 2017;389(10073):1011-1024. doi:10.1016/S0140-6736(16)32409-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/28129987/pubmed" id="28129987" target="_blank">28129987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: Diagnosis and management (clinical guideline 183). 2014; CG183. https://www.nice.org.uk/guidance/cg183.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27718746">
<a name="27718746"></a>Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. <i>Expert Opin Drug Saf</i>. 2016;15(12):1625-1633. doi:10.1080/14740338.2016.1238067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/27718746/pubmed" id="27718746" target="_blank">27718746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439693">
<a name="25439693"></a>Noh SH, Park SR, Yang HK, et al; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. <i>Lancet Oncol.</i> 2014;15(12):1389-1396. doi:10.1016/S1470-2045(14)70473-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/25439693/pubmed" id="25439693" target="_blank">25439693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12065558">
<a name="12065558"></a>O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. <i>J Clin Oncol</i>. 2002;20(12):2812-23. doi:10.1200/JCO.2002.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/12065558/pubmed" id="12065558" target="_blank">12065558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26691173">
<a name="26691173"></a>Oliveira SC, Moniz CM, Riechelmann R, et al. Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. <i>J Gastrointest Cancer. </i>2016;47(1):75-81. doi:10.1007/s12029-015-9790-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/26691173/pubmed" id="26691173" target="_blank">26691173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19164203">
<a name="19164203"></a>Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. <i>J Clin Oncol</i>. 2009;27(16):2598-2603. doi:10.1200/JCO.2008.19.7145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/19164203/pubmed" id="19164203" target="_blank">19164203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25471029">
<a name="25471029"></a>Palmieri G, Buonerba C, Ottaviano M, et al. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial. <i>Future Oncol</i>. 2014;10(14):2141-2147. doi:10.2217/fon.14.144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/25471029/pubmed" id="25471029" target="_blank">25471029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19880439">
<a name="19880439"></a>Palmieri G, Merola G, Federico P, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). <i>Ann Oncol.</i> 2010;21(6):1168-1172. doi:10.1093/annonc/mdp483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/19880439/pubmed" id="19880439" target="_blank">19880439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29855806">
<a name="29855806"></a>Papaxoinis G, Kotoula V, Giannoulatou E, et al. Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. <i>Med Oncol</i>. 2018;35(7):101. doi:10.1007/s12032-018-1160-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/29855806/pubmed" id="29855806" target="_blank">29855806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11935215">
<a name="11935215"></a>Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. <i>Cancer Chemother Pharmacol</i>. 2002;49(3):225-234. doi:10.1007/s00280-001-0408-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/11935215/pubmed" id="11935215" target="_blank">11935215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30922733">
<a name="30922733"></a>Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncol</i>. 2019;20(5):663‐673. doi:10.1016/S1470-2045(18)30915-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/30922733/pubmed" id="30922733" target="_blank">30922733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32162823">
<a name="32162823"></a>Raber I, Warack S, Kanduri J, et al. Fluoropyrimidine-associated cardiotoxicity: A retrospective case-control study. <i>Oncologist</i>. 2020;25(3):e606-e609. doi:10.1634/theoncologist.2019-0762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/32162823/pubmed" id="32162823" target="_blank">32162823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31777367">
<a name="31777367"></a>Rocha A, Almeida HL Jr, Zerwes G, Oliveira Filho UL. Capecitabine-induced subacute cutaneous lupus erythematosus. <i>An Bras Dermatol</i>. 2019;94(5):618-619. doi:10.1016/j.abd.2019.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31777367/pubmed" id="31777367" target="_blank">31777367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33480963">
<a name="33480963"></a>Rugo HS, Im SA, Cardoso F, et al; SOPHIA Study Group. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. <i>JAMA Oncol.</i> 2021;7(4):573-584. doi:10.1001/jamaoncol.2020.7932<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/33480963/pubmed" id="33480963" target="_blank">33480963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21174613">
<a name="21174613"></a>Saif MW. Capecitabine and hand-foot syndrome. <i>Expert Opin Drug Saf</i>. 2011;10(2):159-169. doi:10.1517/14740338.2011.546342<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/21174613/pubmed" id="21174613" target="_blank">21174613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31469628">
<a name="31469628"></a>Sánchez-Gundín J, Torres-Suárez AI, Fernández-Carballido AM, Barreda-Hernández D. Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer. <i>Farm Hosp</i>. 2019;43(5):158-162. doi:10.7399/fh.11161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31469628/pubmed" id="31469628" target="_blank">31469628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31243213">
<a name="31243213"></a>Sasaki K, Zhou Q, Matsumoto Y, Saiki T, Moriyama M, Saijo Y. Treatment of gastric and gastroesophageal cancer patients with hemodialysis by CapeOX. <i>Intern Med</i>. 2019;58(19):2791-2795. doi:10.2169/internalmedicine.2718-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31243213/pubmed" id="31243213" target="_blank">31243213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20375998">
<a name="20375998"></a>Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. <i>Clin Pharmacol Ther</i>. 2010;88(1):60-68. doi:10.1038/clpt.2009.252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/20375998/pubmed" id="20375998" target="_blank">20375998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32678716">
<a name="32678716"></a>Saura C, Oliveira M, Feng YH, et al; NALA Investigators. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. <i>J Clin Oncol</i>. 2020;38(27):3138-3149. doi:10.1200/JCO.20.00147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/32678716/pubmed" id="32678716" target="_blank">32678716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17194911">
<a name="17194911"></a>Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. <i>J Clin Oncol</i>. 2007;25(1):102-109. doi:10.1200/JCO.2006.08.1075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/17194911/pubmed" id="17194911" target="_blank">17194911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17594717">
<a name="17594717"></a>Schneider BJ, El-Rayes B, Muler JH, et al. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. <i>Cancer</i>. 2007;110(4):770-775. doi:10.1002/cncr.22857<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/17594717/pubmed" id="17594717" target="_blank">17594717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27656319">
<a name="27656319"></a>Sharma A, Nguyen HS, Lozen A, et al. Brain metastases from breast cancer during pregnancy. <i>Surg Neurol Int.</i> 2016;7(suppl 23):S603-S606. doi:10.4103/2152-7806.189730<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/27656319/pubmed" id="27656319" target="_blank">27656319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30856044">
<a name="30856044"></a>Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(12):1015‐1027. doi:10.1200/JCO.18.02178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/30856044/pubmed" id="30856044" target="_blank">30856044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32755482">
<a name="32755482"></a>Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. <i>J Clin Oncol</i>. Published online August 5, 2020. doi:10.1200/JCO.20.01364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/32755482/pubmed" id="32755482" target="_blank">32755482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14501389">
<a name="14501389"></a>Sommers KR, Kong KM, Bui DT, Fruehauf JP, Holcombe RF. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. <i>Anticancer Drugs</i>. 2003;14(8):659-662. doi:10.1097/00001813-200309000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/14501389/pubmed" id="14501389" target="_blank">14501389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824724">
<a name="20824724"></a>Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. <i>Cancer</i>. 2011;117(2):268-275. doi:10.1002/cncr.25425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/20824724/pubmed" id="20824724" target="_blank">20824724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26803708">
<a name="26803708"></a>Sun J, Ilich AI, Kim CA, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. <i>Clin Colorectal Cancer</i>. 2016;15(3):257-263. doi:10.1016/j.clcc.2015.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/26803708/pubmed" id="26803708" target="_blank">26803708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17914077">
<a name="17914077"></a>Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. <i>Oncologist</i>. 2007;12(9):1070-1083. doi:10.1634/theoncologist.12-9-1070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/17914077/pubmed" id="17914077" target="_blank">17914077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24885554">
<a name="24885554"></a>Thind G, Johal B, Follwell M, et al. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. <i>Radiat Oncol</i>. 2014;9:124. doi:10.1186/1748-717X-9-124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/24885554/pubmed" id="24885554" target="_blank">24885554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968020">
<a name="17968020"></a>Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. <i>J Clin Oncol</i>. 2007;25(33):5210-5217. doi:10.1200/JCO.2007.12.6557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/17968020/pubmed" id="17968020" target="_blank">17968020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15987918">
<a name="15987918"></a>Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. <i>N Engl J Med</i>. 2005;352(26):2696-704. doi:10.1056/NEJMoa043116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/15987918/pubmed" id="15987918" target="_blank">15987918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USDHHS.1">
<a name="USDHHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. Updated September 2016. Accessed October 5, 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11689577">
<a name="11689577"></a>Van Cutsem E, Twelves C, Cassidy J, et al; Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. <i>J Clin Oncol</i>. 2001;19(21):4097-4106. doi:10.1200/JCO.2001.19.21.4097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/11689577/pubmed" id="11689577" target="_blank">11689577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34348673">
<a name="34348673"></a>van Rees JM, Hartman W, Nuyttens JJME, et al. Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. <i>BMC Gastroenterol</i>. 2021;21(1):313. doi:10.1186/s12876-021-01886-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/34348673/pubmed" id="34348673" target="_blank">34348673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16237130">
<a name="16237130"></a>Videnovic A, Semenov I, Chua-Adajar R, et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. <i>Neurology</i>. 2005;65(11):1792-4; discussion 1685. doi:10.1212/01.wnl.0000187313.83515.7e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/16237130/pubmed" id="16237130" target="_blank">16237130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-vonBorstel.2009">
<a name="vonBorstel.2009"></a>von Borstel R, O'Neil J, Bamat M. Vistonuridine: An orally administered, life-saving antidote for 5-fluorouracil (5FU) overdose [abstract 9616]. <i>J Clin Oncol</i>. 2009;27(15s):9616.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15763604">
<a name="15763604"></a>Walko CM, Lindley C. Capecitabine: a review. <i>Clin Ther</i>. 2005;27(1):23-44. doi:10.1016/j.clinthera.2005.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/15763604/pubmed" id="15763604" target="_blank">15763604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16516276">
<a name="16516276"></a>Wolf JK, Bodurka DC, Verschraegen C, et al. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. <i>Gynecol Oncol</i>. 2006;102(3):468-474. doi:10.1016/j.ygyno.2005.12.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/16516276/pubmed" id="16516276" target="_blank">16516276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xeloda.2021.05">
<a name="Xeloda.2021.05"></a>Xeloda (capecitabine) [prescribing information]. South San Francisco, CA: Genentech USA Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xeloda.2021.04">
<a name="Xeloda.2021.04"></a>Xeloda (capecitabine) [product monograph]. Oakville, Ontario, Canada: Xediton Pharmaceuticals Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18756532">
<a name="18756532"></a>Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. <i>Cancer</i>. 2008;113(8):2046-2052. doi:10.1002/cncr.23810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/18756532/pubmed" id="18756532" target="_blank">18756532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28715540">
<a name="28715540"></a>Yap YS, Kwok LL, Syn N, et al. Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: A randomized clinical trial. <i>JAMA Oncol</i>. 2017;3(11):1538-1545. doi:10.1001/jamaoncol.2017.1269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/28715540/pubmed" id="28715540" target="_blank">28715540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26160973">
<a name="26160973"></a>Yokokawa T, Kawakami K, Mae Y, et al. Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy. <i>Ann Pharmacother</i>. 2015;49(10):1120-1124. doi:10.1177/1060028015594451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/26160973/pubmed" id="26160973" target="_blank">26160973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30333392">
<a name="30333392"></a>Yoshimura K, Tokunaga S, Daga H, Inoue M. Capecitabine-induced Leukoencephalopathy.<i> Intern Med</i>. 2019;58(4):621-622. doi:10.2169/internalmedicine.0961-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/30333392/pubmed" id="30333392" target="_blank">30333392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31558182">
<a name="31558182"></a>Zhao J, Zhang X, Cui X, Wang D, Zhang B, Ban L. Loss of fingerprints as a side effect of capecitabine therapy: Case report and literature review. <i>Oncol Res</i>. 2020;28(1):103-106. doi:10.3727/096504019X15605078731913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capecitabine-drug-information/abstract-text/31558182/pubmed" id="31558182" target="_blank">31558182</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8839 Version 434.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
